Tumorlet and antifibrotic treatment
Authors:
J. Krynská
Authors place of work:
Branislavova 1415/1, 266 01 Beroun
Published in the journal:
Reviz. posud. Lék., 23, 2020, č. 3-4, s. 79-82
Category:
Original Articles, Review Articles, Case Reports
Summary
Pulmonary fibrotic processes are very inhomogeneous etiologies, destructive changes in lung tissue can occur even in the rare occurrence of hyperplasia of neuroendocrine cells in the lung parenchyma, considered as precancerous. Treatments are ambiguous, often only monitoring is recommended, some studies refer to the concomitant production of profibrotic factors VEGF and TGF-β1 and consider the action of antifibrotics.
Keywords:
diffuse idiopathic neuroendocrine cell hyperplasia – DIPNECH – preneoplasia pulmonary carcinoid tumors – tumorlet – antifibrotic therapy – nintedanib
Zdroje
1. Ping, He., Xia, Gu., Qinian, Wu., Yunen, Lin., Yingying, Gu., Jianxing, He.: Pulmonary carcinoid tumorlet without underlying lung disease: analysis of its relationship to fibrosis. Journal of Thoracic Disease, December 2012.
2. Wirtschafter E., Walts, A. E., Liu, S. T., Marchevsky, A. M.: Diffuse Idiopathic Pulmonary Neuroendocrine Cell Hyperplasia of the Lung (DIPNECH): Current Best Evidence. National Library od Medicine, Oct. 2015.
3. Myint, Z. W., McCormick, J., Chauhan A., Behrens, E., Lowell, B. A.: Management of Diffuse Idiopathic Pulmonary Neuro-endocrine Cell Hyperplasia: Review and a Single Center Expe-rience. Cureus, September 13, 2019.
Štítky
Medical assessment Occupational medicineČlánok vyšiel v časopise
Medical Revision
2020 Číslo 3-4
Najčítanejšie v tomto čísle
- Control medical examinations of disability in mental disorders
- Principles of correct formulation of conclusions of assessment, use of statements and determination of validity of assessment in assessing disability
- Posuzování zdravotního stavu a soběstačnosti/schopnosti samostatného života, závislosti, příspěvek na péči
- Assessment issues in children and adolescents